Article thumbnail

Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study

By Max Lataillade, Jennifer Chiarella, Rong Yang, Steven Schnittman, Victoria Wirtz, Jonathan Uy, Daniel Seekins, Mark Krystal, Marco Mancini, Donnie McGrath, Birgitte Simen, Michael Egholm and Michael Kozal
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2880604
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). Atazanavir/Ritonavir vs Lopinavir/Ritonavir in AntiretroviralNaı ¨ve HIV-1-Infected Patients:
  2. (2007). Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance.
  3. (2007). Comparison of traditional plasmid-based clonal sequencing to 454 ultra-deep sequencing for HIV clinical isolates with reverse transcriptase (RT) mutations at K65R and L74V.
  4. (2007). DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations.
  5. (1997). DNA sequencing with chainterminating inhibitors.
  6. (2009). Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance:
  7. (2009). Drug Resistant HIV.
  8. (2006). Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
  9. (2007). Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
  10. (2010). Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
  11. (1996). Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.
  12. (2006). External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.
  13. for the BMS AI2424138 study group (2008) The CASTLE Study 48 week results: The impact of HIV subtypes and baseline resistance on treatment outcomes and the emergence of resistance.
  14. (2005). Genome sequencing in microfabricated high-density picolitre reactors.
  15. (2003). Human immunodeficiency virus reverse transcriptase and protease sequence database.
  16. (2008). Impact of HIV viral diversity and baseline resistance on treatment outcomes and the emergence of resistance: The CASTLE study 48-week results.
  17. (2010). Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
  18. (2009). Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral Treatment–Naive patients significantly impact treatment outcomes.
  19. (2007). Low-level K65R mutation in HIV-1 reverse transcriptase of treatmentexperienced patients exposed to abacavir or didanosine.
  20. (2009). LowAbundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use.
  21. (2008). Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy.
  22. (2009). Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
  23. (2008). Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
  24. (2009). Pre-existing low levels of K103N HIV-1 RT mutation above a threshold is associated with virologic failure in treatment naı ¨ve patients undergoing EFVcontaining antiretroviral treatment.
  25. (2010). Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
  26. (2007). Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.
  27. (2008). Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV1-infected subjects.
  28. (2003). Quantitative detection of low-copy-number mRNAs differing at single nucleotide positions.
  29. (2010). Resistance PLoS ONE | www.plosone.org 6
  30. (2006). Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.
  31. (1981). Statistical Methods for Rates and Proportions John Wiley and Sons.
  32. (2004). Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
  33. (2010). Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.
  34. (2008). Transmission of HIV-1 minority-resistant variants and response to firstline antiretroviral therapy.
  35. (2008). Virologic Success of Different Strategies for Initial Antiretroviral Therapy Regimens Is Predicted by the Type and Detection Level of Minor Drug Resistant Variants Detected by Ultra Deep Sequencing: